Calamos Wealth Management LLC Buys 2,407 Shares of Eli Lilly and Company (NYSE:LLY)

Calamos Wealth Management LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,691 shares of the company’s stock after purchasing an additional 2,407 shares during the quarter. Eli Lilly and Company comprises approximately 1.3% of Calamos Wealth Management LLC’s investment portfolio, making the stock its 15th biggest position. Calamos Wealth Management LLC’s holdings in Eli Lilly and Company were worth $25,348,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares during the period. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares during the period. Mascagni Wealth Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $43,000. Prudent Man Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $48,000. Finally, O Brien Wealth Partners LLC boosted its position in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after acquiring an additional 12 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Up 0.0%

Shares of NYSE LLY opened at $779.60 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The company has a market cap of $738.85 billion, a price-to-earnings ratio of 63.43, a PEG ratio of 1.14 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The stock has a 50-day moving average price of $773.61 and a two-hundred day moving average price of $799.72.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the company earned $2.58 EPS. The business’s quarterly revenue was up 45.2% compared to the same quarter last year. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.77%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. UBS Group cut their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price objective for the company. Finally, Wall Street Zen cut shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday, June 28th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.